Evolent Health’s (EVH) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Evolent Health (NYSE:EVH) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $20.00 price target on the technology company’s stock.

A number of other brokerages have also weighed in on EVH. JPMorgan Chase & Co. lifted their target price on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. KeyCorp initiated coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial restated a “buy” rating and set a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. Oppenheimer lowered their price objective on Evolent Health from $45.00 to $34.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, Stephens downgraded shares of Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $38.00 to $16.00 in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $30.70.

Evolent Health Trading Down 4.6 %

EVH stock opened at $14.44 on Tuesday. Evolent Health has a 12-month low of $13.31 and a 12-month high of $35.00. The firm’s 50-day moving average price is $26.17 and its two-hundred day moving average price is $24.61. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.08 and a current ratio of 1.04.

Insider Activity

In other Evolent Health news, President Daniel Joseph Mccarthy sold 23,693 shares of Evolent Health stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.89, for a total value of $731,876.77. Following the completion of the sale, the president now owns 198,809 shares of the company’s stock, valued at approximately $6,141,210.01. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the sale, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Daniel Joseph Mccarthy sold 23,693 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the transaction, the president now owns 198,809 shares in the company, valued at $6,141,210.01. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 307,291 shares of company stock valued at $9,290,385 over the last three months. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Evolent Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Scout Investments Inc. purchased a new position in shares of Evolent Health during the 1st quarter valued at about $5,760,000. Harbor Capital Advisors Inc. boosted its position in shares of Evolent Health by 140.0% in the third quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock worth $11,946,000 after purchasing an additional 246,400 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Evolent Health by 11.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company’s stock worth $23,522,000 after purchasing an additional 75,376 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Evolent Health during the 2nd quarter valued at $2,705,000. Finally, Gabelli Funds LLC lifted its stake in shares of Evolent Health by 21.5% during the 1st quarter. Gabelli Funds LLC now owns 638,500 shares of the technology company’s stock valued at $20,936,000 after buying an additional 113,000 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.